Filter
Exclude
Time range
-
Near
Jun 12
Replying to @haze_OSIC
dead before release wow #SteamCharts #NewData
3
1,949
まっちゃ︎︎‎‎🫧🎀/🐰🏰/🍥🐩💯/🐶🎀☁/🩷💛🩵/🐾🌸/🏡🎀 retweeted
とてもご丁寧に サムネイルの商品はリメイク後のものなので、お求めの際はリンク下段の「NewData」をインストールしてください。 と書いてくださっています!! NewDataの方を入れてね 分からなかったら天音のあが教えます。 こんな素敵なハートで天使な可愛いペンラ🥹🥹🫶🤍 余りにも最高です
1
7
244
#NewData Shows Trump’s Promise to Revive Manufacturing Is Struggling #Trump’s promised “golden age” of #American #manufacturing is collapsing under the weight of its own numbers as factory spending sinks and #jobs disappear, according to humiliating new official government data. The president swept back into the White House in January 2025 vowing to “supercharge our domestic industrial base,” leaning on aggressive tariffs and arm-twisting to drag companies into building plants on #US. soil. Eighty-four firms duly pledged more than $900 billion to expand American manufacturing. But almost none of it is being built, according to numbers reported by the #FinancialTimes. The outlet found that private spending on factory construction slumped to $15.2 billion in April—down roughly 16 percent since Trump’s second term began—while 👉77,000 factory jobs have #evaporated over the same stretch. #dailybeast
1
3
95
May 5
Time to play CD’s available for purchase as of NOW 🗣️ QR code inside with an unreleased single from me . Use my password “newdata” to unlock after you purchase Linktr.ee/ripxl 🌐🌐🌐
4
6
261
📊#NewData Somalia’s 2025 livestock export data, produced by @CentralBankSo is now publicly available. With support from #HoADRIVE, this data improves visibility on export volumes, values, and market flows across. Visit 🔗stip.gov.so to explore this trade data.
1
4
115
後輩から聞いた。変数名を`data`、`data2`、`newData`、`finalData`って名付けてコード書いてたら、レビューで『これ全部何のデータ?』って聞かれて答えられなかった。1週間後に自分で見ても理解できなかったって。
4
667
変数名つけるのに15分悩んだ結果 data → data2 → newData → finalData → realFinalData → temp 最終的に temp で動いてるの怖すぎる
5
92
#Newdata from our partnership with @RANDCorporation challenge a common narrative ➡️ 68% of #homeschooling parents either currently use or would use public funding — such as ESAs or tax credits — to homeschool their child. Full report: education.jhu.edu/edpolicy/p…
1
2
94
By expanding national wastewater surveillance, these #data support infectious disease epidemiology, early warning, and public health decision-making at scale. 🔗 Read the article: sciencedirect.com/science/ar… #WastewaterSurveillance #NewData

3
177
📢#OutNow❗️ @FAOStatistics & @WorldBank brief under @50x2030 presents key insights on land and holding size, crop output and yields, livestock rearing and labour use in Nigeria during ag season 2022/23. #NewData to inform better policies🌾📊 📘👉openknowledge.fao.org/handle…
9
12
429
新しいRemixはfetchしてdata = newData; isLoading = false; this.update() か?うーん これ頻出すぎるのでなんか良いパターン入りそう
1
2
417
We presented new data at the 67th ASH® Annual Meeting and Exposition! If you didn’t get a chance to learn more during #ASH25, let's schedule a post-meeting discussion: neogenomics.com/about-neogen… #NewData #Oncology #RWD
2
73
How live collaboration works (like when two people edit the same doc in real time)? > Client: sends changes → socket.emit('update', { room, newData }) > Server: broadcasts to others → socket.to(room).emit('receive_update', newData) > Client: receives update & refreshes UI (with a loop guard to prevent re-sending). That’s the basic loop behind real-time collaboration....

2
52
🚨‼️ HER2CLIMB-05 Phase 3 trial shows adding tucatinib to first-line maintenance therapy improves PFS in HER2 metastatic BC #breastonc #clinicaltrials #newdata
14 Oct 2025
NEWS FROM Industry: HER2CLIMB-05 Update Source: Pfizer announcement, report by Business wire buff.ly/27ChwaI Pfizer announced positive topline results from the Phase 3 HER2CLIMB-05 trial, which evaluated the addition of the tyrosine kinase inhibitor tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic #BreastCancer (MBC). The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo, with a safety profile consistent with known effects of the individual agents. These findings suggest that incorporating tucatinib into 1L maintenance may further delay disease progression and potentially advance treatment standards for HER2 MBC, a population that continues to face high relapse rates despite current therapies. awaiting full results!! @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
3
489
13 Aug 2025
ある人物の嘘をずっと記録していますが、昨日もNewDataをゲット❣️ 良くもまあ息をする様に嘘を付けるものだと感心します!
1
97
Replying to @stkirsch
Steve, I think your KCOR method has merit. I think it would be worth using the "log ratio of LOESS trendlines" to capture the ratio of differences in baseline: (V/Vbase)/(U/Ubase) Here's a model with random variation between the groups in the first 50 weeks then a steady rise to a 10% increase in mortality over the next 50 weeks. LOESS smooths the variability so is more dynamic than a fixed linear baseline. R Code below. uvr <- rnorm(100, 200, 10) vxr <- rnorm(100, 250, 10) * c(rnorm(50,1,0.02), seq(1, 1.1, length.out = 50)) weeks <- 1:100 # --- plot base series --- uvr.mean<-mean(uvr[1:12]) vxr.mean<-mean(vxr[1:12]) plot(weeks, vxr/vxr.mean, pch = 21, col = "blue", xlab = "Week", ylab = "Mortality rate ratio") lines(weeks, vxr/vxr.mean, lwd = 1, col = "blue") points(weeks, uvr/uvr.mean, pch = 21, col = "brown") lines(weeks, uvr/uvr.mean, lwd = 1, col = "brown") scan() # 1) baselines and normalization to "ratio-to-baseline" base_uvr <- mean(uvr[1:12], na.rm = TRUE) base_vxr <- mean(vxr[1:12], na.rm = TRUE) uvr_n <- uvr / base_uvr vxr_n <- vxr / base_vxr # 2) fit LOESS on the normalized series span <- 0.25 # tweak as desired (0.2–0.4 is a nice range) lo_uvr <- loess(uvr_n ~ weeks, span = span, degree = 1, family = "gaussian") lo_vxr <- loess(vxr_n ~ weeks, span = span, degree = 1, family = "gaussian") pred_grid <- data.frame(weeks = weeks) uvr_lo <- predict(lo_uvr, newdata = pred_grid) vxr_lo <- predict(lo_vxr, newdata = pred_grid) # 3) ratio of LOESS curves (VXR ÷ UVR). >1 means VXR higher than UVR. ratio_lo <- vxr_lo / uvr_lo op <- par(mfrow = c(1, 2), mar = c(4, 4, 2, 1)) ## ---- Plot 1: normalized series LOESS for both cohorts ---- plot(weeks, uvr_n, type = "n", ylim = range(c(uvr_n, vxr_n), na.rm = TRUE), xlab = "Week", ylab = "Rate / Baseline (weeks 1–12)", main = "Normalized rates LOESS") # shade first 12 weeks rect(0.5, par("usr")[3], 12.5, par("usr")[4], col = adjustcolor("grey80", 0.25), border = NA) abline(h = 1, col = "grey50", lty = 3) # raw points/lines points(weeks, uvr_n, pch = 21, col = "brown") lines(weeks, uvr_n, col = "brown") points(weeks, vxr_n, pch = 21, col = "blue") lines(weeks, vxr_n, col = "blue") # LOESS trendlines lines(weeks, uvr_lo, lwd = 3, col = adjustcolor("brown", 0.9), lty = 1) lines(weeks, vxr_lo, lwd = 3, col = adjustcolor("blue", 0.9), lty = 1) legend("topleft", legend = c("UVR (norm.)", "VXR (norm.)", "UVR LOESS", "VXR LOESS"), col = c("brown", "blue", "brown", "blue"), lty = c(1, 1, 1, 1), lwd = c(1, 1, 3, 3), bty = "n", cex = 0.9) ## ---- Plot 2: centered log ratio barplot ---- log_ratio_lo <- log(ratio_lo) # natural log # symmetric axis limits around 0 ylim_range <- max(abs(log_ratio_lo), na.rm = TRUE) bar_cols <- ifelse(weeks <= 12, adjustcolor("steelblue", 0.8), adjustcolor("grey60", 0.9)) bp <- barplot(log_ratio_lo, border = NA, col = bar_cols, space = 0.2, xlab = "Week", ylab = "log(VXR LOESS / UVR LOESS)", main = "Log ratio of LOESS trendlines", ylim = c(-ylim_range, ylim_range)) abline(h = 0, col = "grey30", lty = 2) # 0 = equal legend("topright", legend = c("Weeks 1–12", "Weeks 13–100"), fill = c(adjustcolor("steelblue", 0.8), adjustcolor("grey60", 0.9)), border = NA, bty = "n", cex = 0.9) par(op) @canceledmouse @ManDownUnder76 @m_a_n_u______
5
3
18
1,201
🧬 New data from @Snau_PhD suggest a modest association between alcohol intake 🍺 and increased #PancreaticCancer risk, even among nonsmokers. 🔍 Study led by Pietro Ferrari, MSc, PhD 📄 Details: ascopost.com/news/may-2025/a… #Oncology #Epidemiology #CancerRisk #NewData
2
998